Biblio
Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023;43:e390802.
. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium. J Hematol Oncol. 2023;16(1):122.
How disease stage impacts the rate of second primary malignancies in patients with diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2020;18(3):147-149.
. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022.
Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy. Clin Lymphoma Myeloma Leuk. 2022.
. Cellular therapy in lymphoma. Hematol Oncol. 2023.